Document Type : Research articles


Department of Anesthesiology, Second Hospital of Jilin University, Changchun, China


Background: To study the effect of dexmedetomidine on oxidative stress response and the expression of intracellular adhesion factor-1 (ICAM-1) and S100B in patients with traumatic brain injury (TBI).
Objectives: This study aimed to discusses the effects of dexmedetomidine on oxidative stress response and ICAM-1 and S100B expression in patients with TBI to investigate its protective effect on oxidative stress and brain damage in patients with TBI.
Methods: The TBI patients treated in our hospital from May 2017 to April 2020 were enrolled in the study and divided into control and treatment groups by the random number table method. The treatment group was administered with dexmedetomidine injection via an intravenous pump based on the conventional treatment in the control group. Glasgow coma scale (GCS) and Glasgow outcome scale (GOS) were used to evaluate the patients injury, recovery, and prognosis. ELISA method was employed to detect four oxidative stress index levels, including serum superoxide dismutase (SOD), lipid peroxidation (LPO), malondialdehyde (MDA), and total antioxidant capacity (TAC), as well as ICAM-1 and S100B levels upon admission and at different time points after the operation.
Results: On the 3rd and 14th day after the operation, the treatment group had a higher GCS score, compared to the control group (P<0.05). Furthermore, on the 30th, 90th, and 180th days after discharge, the treatment group had a higher GOS score than the control group (P<0.05). On the 3rd, 5th, and 14th days after operation, the treatment group had higher SOD activity than the control group (P<0.05). Immediately after the operation, on the 3rd, 5th, and 14th after the operation, the treatment group had higher LPO levels than the control group (P<0.05). Moreover, on the 3rd, 5th, and 14th days after the operation, blood MDA levels gradually decreased in both groups, which was lower in the treatment group than that in the control group (P<0.05). On the 3rd, 5th, and 14th after the operation, the treatment group had higher TAC activity in the blood, compared to that in the control group (P<0.05). On the 3rd, 5th, and 14th days after the operation, the treatment group had lower S100B levels than that in the control group (P<0.05).
Conclusion: Dexmedetomidine can relieve TBI-induced oxidative stress state and reduce the levels of brain injury markers (ICAM-1, S100B), which has a protective effect on the brain tissue with TBI.


  1. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80(1):6-15. doi: 10.1227/NEU.0000000000001432. [PubMed: 27654000].
  2. Simon DW, McGeachy MJ, Bayır H, Clark RS, Loane DJ, Kochanek PM. The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol. 2017;13(3):171-91. doi: 10.1038/nrneurol.2017.13. [PubMed: 28186177].
  3. Dixon KJ. Pathophysiology of traumatic brain injury. Phys Med Rehabil Clin N Am. 2017;28(2):215-25. doi: 10.1016/j.pmr.2016.12.001. [PubMed: 28390509].
  4. Liou YJ, Wei HT, Chen MH, Hsu JW, Huang KL, Bai YM, et al. Risk of traumatic brain injury among children, adolescents, and young adults with attention-deficit hyperactivity disorder in Taiwan. J Adolesc Health. 2018;63(2):233-8. doi: 10.1016/j.jadohealth.2018.02.012. [PubMed: 29970331].
  5. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16(12):987-1048. doi: 10.1016/S1474-4422(17)30371-X. [PubMed: 29122524].
  6. Wang D, Xu X, Wu YG, Lyu L, Zhou ZW, et al. Dexmedetomidine attenuates traumatic brain injury: action pathway and mechanisms. Neural Regen Res. 2018;13(5):819-26. doi: 10.4103/1673-5374.232529. [PubMed: 29863012].
  7. Singh S, Chouhan RS, Bindra A, Radhakrishna N. Comparison of effect of dexmedetomidine and lidocaine on intracranial and systemic hemodynamic response to chest physiotherapy and tracheal suctioning in patients with severe traumatic brain injury. J Anesth. 2018;32(4):518-23. doi: 10.1007/s00540-018-2505-9. [PubMed: 29725828].
  8. Gómez-Ramírez S, Bisbe E, Shander A, Spahn DR, Muñoz M. Management of perioperative iron deficiency anemia. Acta Haematol. 2019;142(1):21-9. doi: 10.1159/000496965. [PubMed: 30970362].
  9. Galgano M, Toshkezi G, Qiu X, Russell T, Chin L, Zhao LR. Traumatic brain injury: current treatment strategies and future endeavors. Cell Transplant. 2017;26(7):1118-30. doi: 10.1177/0963689717714102. [PubMed: 28933211].
  10. Meshkini A, Meshkini M, Sadeghi-Bazargani H. Citicoline for traumatic brain injury: a systematic review & meta-analysis. J Inj Violence Res. 2017;9(1):41–50. doi: 10.5249/jivr.v9i1.843. [PubMed: 28039682].
  11. Shen M, Wang S, Wen X, Han XR, Wang YJ, Zhou XM, et al. Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury. Biomed Pharmacother. 2017;95:885-93. doi: 10.1016/j.biopha.2017.08.125. [PubMed: 28903184].
  12. Rong H, Zhao Z, Feng J, Lei Y, Wu H, Sun R, et al. The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. Brain Behav Immun. 2017;64:195-207. doi: 10.1016/j.bbi.2017.03.006. [PubMed: 28302458].
  13. Fehily B, Fitzgerald M. Repeated mild traumatic brain injury: potential mechanisms of damage. Cell Transplant. 2017;26(7):1131-55. doi: 10.1177/0963689717714092. [PubMed: 28933213].
  14. Khatri N, Thakur M, Pareek V, Kumar S, Sharma S, Datusalia AK. Oxidative stress: major threat in traumatic brain injury. CNS Neurol Disord Drug Targets. 2018;17(9):689-95. doi: 10.2174/1871527317666180627120501. [PubMed: 29952272].
  15. Chen YH, Huang EY, Kuo TT, Miller J, Chiang YH, Hoffer BJ. Impact of traumatic brain injury on dopaminergic transmission. Cell Transplant. 2017;26(7):1156-68. doi: 10.1177/0963689717714105. [PubMed: 28933212].
  16. Lutton EM, Razmpour R, Andrews AM, Cannella LA, Son YJ, Shuvaev VV, et al. Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury. Sci Rep. 2017;7(1):3846. doi: 10.1038/s41598-017-03309-4. [PubMed: 28630485].
  17. Thelin EP, Nelson DW, Bellander BM. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien). 2017;159(2):209-25. doi: 10.1007/s00701-016-3046-3. [PubMed: 27957604].
  18. Han JH, Kim DO, Yi JW, Park SW, Kang WJ, Choi YK, et al. Dexmedetomidine, α2-adrenoceptor agonist, does not induce apoptosis in the brachial plexus of rats. Anim Cells Syst. 2014;18(6):407-15. doi: 10.1080/19768354.2014.983969.
  19. Choi IY, Hwang L, Jin JJ, Ko IG, Kim SE, Shin MS, et al. Dexmedetomidine alleviates cerebral ischemia-induced short-term memory impairment by inhibiting the expression of apoptosis-related molecules in the hippocampus of gerbils. Exp Ther Med. 2017;13(1):107-16. doi: 10.3892/etm.2016.3956. [PebMed: 28123477].
  20. Li Y, Liu S. The effect of dexmedetomidine on oxidative stress response following cerebral ischemia-reperfusion in rats and the expression of intracellular adhesion molecule-1 (ICAM-1) and S100B. Med Sci Monit. 2017;23:867-73. doi: 10.12659/msm.899855. [PebMed: 28212354].
  21. Ning Q, Liu Z, Wang X, Zhang R, Zhang J, Yang M, et al. Neurodegenerative changes and neuroapoptosis induced by systemic lipopolysaccharide administration are reversed by dexmedetomidine treatment in mice. Neurol Res. 2017;39(4):357-66. doi: 10.1080/01616412.2017.1281197. [PebMed: 28173746].
  22. Lu P, Lei S, Li W, Lu Y, Zheng J, Wang N, et al. Dexmedetomidine Protects neural stem cells from ketamine-induced injury. Cell Physiol Biochem. 2018;47(4):1377-88. doi: 10.1159/000490823. [PebMed: 29929189].
  23. Kim E, Kim HC, Lee S, Ryu HG, Park YH, Kim JH, et al. Dexmedetomidine confers neuroprotection against transient global cerebral ischemia/reperfusion injury in rats by inhibiting inflammation through inactivation of the TLR-4/NF-κB pathway. Neurosci Lett. 2017;649:20-7. doi: 10.1016/j.neulet.2017.04.011. [PebMed: 28392361].